4/A: University of Texas/Texas A&M Investment Management Corrects Form 4 Filing for Aileron Therapeutics (ALRN)
SEC Form 4/A (Amendment)
The University of Texas/Texas A&M Investment Management Company filed an amended Form 4 to correct errors in a previous filing regarding sales of Aileron Therapeutics (ALRN) common stock.
Summary
- The University of Texas/Texas A&M Investment Management Company (UTIMCO) filed an amendment to a previous Form 4 filing.
- The amendment corrects errors in the original filing related to sales of Aileron Therapeutics (ALRN) common stock that were incorrectly reported.
- The corrected filing reflects sales of common stock on May 1, 2024, at prices ranging from $4.10 to $4.32.
- Following these transactions, UTIMCO beneficially owns 1,790,142 shares of Aileron Therapeutics common stock.
- UTIMCO holds these shares on behalf of the Board of Regents of the University of Texas System and has investment and voting power over them.
Sentiment
Score: 7
Explanation: The document is a routine regulatory filing. The correction of an error is a neutral event.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders or significant shareholders of a publicly traded company buy or sell shares. Amendments are sometimes necessary to correct errors in previous filings.
Key Dates
| Date | Description |
|---|---|
| 05/01/2024 | Date of the corrected stock sales transactions. |
| 05/01/2024 | Date of the original Form 4 filing containing errors. |
| 05/14/2024 | Date of the amended Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.